About fulcrum therapeutics inc - FULC
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
FULC At a Glance
Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139
| Phone | 1-617-651-8851 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -74,880,000.00 | |
| Sector | Health Technology | Employees | 55 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
FULC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.158 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.446 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.017 |
FULC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,361,454.545 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
FULC Liquidity
| Current Ratio | 27.397 |
| Quick Ratio | 27.397 |
| Cash Ratio | 27.001 |
FULC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -23.885 |
| Return on Equity | -25.296 |
| Return on Total Capital | -21.067 |
| Return on Invested Capital | -24.856 |
FULC Capital Structure
| Total Debt to Total Equity | 1.846 |
| Total Debt to Total Capital | 1.813 |
| Total Debt to Total Assets | 1.759 |
| Long-Term Debt to Equity | 1.157 |
| Long-Term Debt to Total Capital | 1.136 |